Now showing items 1-7 of 7
Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer
(2015-06-02) - Journal article,
Monocarboxylate Transporter 2 (MCT2) is a major pyruvate transporter encoded by the SLC16A7 gene. Recent studies pointed to a consistent overexpression of MCT2 in prostate cancer (PCa) suggesting MCT2 as a putative biomarker ...
The early effects of rapid androgen deprivation on human prostate cancer
(2016-08) - Journal article,
The androgen receptor (AR) is the dominant growth factor in prostate cancer (PCa). Therefore, understanding how ARs regulate the human transcriptome is of paramount importance. The early effects of castration on human PCa ...
HES5 silencing is an early and recurrent change in prostate tumourigenesis
(2015-04-01) - Journal article,
Prostate cancer is the most common cancer in men, resulting in over 10 000 deaths/year in the UK. Sequencing and copy number analysis of primary tumours has revealed heterogeneity within tumours and an absence of recurrent ...
The role of TET-mediated DNA hydroxymethylation in prostate cancer
(2018-02-15) - Journal item,
Ten-eleven translocation (TET) proteins are recently characterized dioxygenases that regulate demethylation by oxidizing 5-methylcytosine to 5-hydroxymethylcytosine and further derivatives. The recent finding that 5hmC is ...
Mining human prostate cancer datasets : the “camcAPP” shiny app
(2017-03) - Journal item,
The importance of DNA methylation in prostate cancer development
(2017-02) - Journal item,
After briefly reviewing the nature of DNA methylation, its general role in cancer and the tools available to interrogate it, we consider the literature surrounding DNA methylation as relating to prostate cancer. Specific ...
Integration of copy number and transcriptomics provides risk stratification in prostate cancer : a discovery and validation cohort study
(2015-09) - Journal article,
Background : Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundamental to improving the way we treat this disease. As yet, there are no validated descriptions of prostate cancer subgroups ...